EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Modern Pathology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/modpathol.2013.132PMID 23887300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TSC1 involvement in bladder cancer: diverse effects and therapeutic implications

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Molecular pathology of urinary bladder cancer

  2013cited by this paper
• Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.

  2013cited by this paper
• Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers

  2013cited by this paper
• Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.

  2013cited by this paper
• KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas

  2012cited by this paper
• Bladder Cancer: General Features

  2012cited by this paper
• Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

  2012cited by this paper
• Molecular pathology of lung cancer: key to personalized medicine

  2012cited by this paper
• American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

  2011cited by this paper
• The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.

  2011cited by this paper
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

  2011cited by this paper
• A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1

  2011cited by this paper
• Glandular lesions of the urinary bladder:clinical significance and differential diagnosis

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome

  2011cited by this paper
• Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers.

  2011cited by this paper
• Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry.

  2010cited by this paper
• Understanding resistance to EGFR inhibitors—impact on future treatment strategies

  2010cited by this paper
• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

  2010cited by this paper
• Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

  2010cited by this paper
• EML4-ALK: honing in on a new target in non-small-cell lung cancer.

  2009cited by this paper
• Primary Signet-ring Cell Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Study of 5 Cases

  2009cited by this paper
• EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

  2009cited by this paper
• Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2009cited by this paper
• Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder.

  2009cited by this paper
• The present and future burden of urinary bladder cancer in the world

  2009cited by this paper
• Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma

  2009cited by this paper
• Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder.

  2008cited by this paper
• Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

  2008cited by this paper
• Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis

  2008cited by this paper
• EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

  2008cited by this paper
• High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder.

  2007cited by this paper
• Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder

  2007cited by this paper
• Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

  2007cited by this paper
• Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients.

  2006cited by this paper
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Malignant non-urothelial neoplasms of the urinary bladder: a review.

  2003cited by this paper
• Primary adenocarcinoma of the urinary bladder: a report of 185 cases.

  1998cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases

  1991cited by this paper

• Primary Urethral Adenocarcinoma Harbors Recurrent KRAS and EGFR Alterations.

  2025cites this paper
• Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study

  2024cites this paper
• Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets

  2023cites this paper
• Comparative genomic profiling of glandular bladder tumours

  2020cites this paper
• Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma

  2020cites this paper
• TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder

  2020cites this paper
• Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma

  2018cites this paper
• Evaluation of cellular transformation and tumor aggressiveness factor expression in urinary bladder lesions and transitional cell carcinoma special variants in relation to bilharziasis

  2017cites this paper
• Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma

  2017cites this paper
• Pathology of the Urinary Bladder: An Algorithmic Approach

  2016cites this paper
• Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in‐situ hybridization for the detection of anaplastic lymphoma kinase alterations

  2015cites this paper
• The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

  2015cites this paper
• Pathology and Pathogenesis of Bladder Tumors

  2014cites this paper